|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 294.76 USD | -1.17% |
|
-0.17% | +13.09% |
| 07-11 | Amgen Inc., Q1 2025 Earnings Call, May 01, 2025 | |
| 07-11 | HSBC Adjusts Price Target on Amgen to $337 From $346, Maintains Buy Rating | MT |
| Capitalization | 158B 136B 127B 118B 218B 13,650B 243B 1,531B 578B 6,400B 595B 582B 23,525B | P/E ratio 2025 * |
22.5x | P/E ratio 2026 * | 19.9x |
|---|---|---|---|---|---|
| Enterprise value | 204B 175B 163B 151B 279B 17,537B 312B 1,967B 742B 8,222B 764B 748B 30,224B | EV / Sales 2025 * |
5.77x | EV / Sales 2026 * | 5.5x |
| Free-Float |
99.85% | Yield 2025 * |
3.25% | Yield 2026 * | 3.42% |
More valuation ratios
* Estimated data
More news
Last Transcript: Amgen Inc.
More recommendations
More press releases
| 1 day | -1.17% | ||
| 1 week | -0.17% | ||
| Current month | +5.57% | ||
| 1 month | +1.77% | ||
| 3 months | +6.30% | ||
| 6 months | +8.32% | ||
| Current year | +13.09% |
| 1 week | 291.94 |  | 301 |
| 1 month | 267.83 | | 302.38 |
| Current year | 257.05 | | 335.88 |
| 1 year | 253.3 | | 346.85 |
| 3 years | 211.71 | | 346.85 |
| 5 years | 198.64 | | 346.85 |
| 10 years | 130.09 | | 346.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 62 | 2012-04-30 |
Peter Griffith
DFI | Director of Finance/CFO | 66 | 2019-12-31 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 2023-12-17 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 62 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 64 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 70 | 2011-12-31 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 5.08% | 137 M€ | -1.57% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.17% | -0.17% | -11.03% | +19.18% | 158B | ||
| +1.34% | -2.69% | -10.00% | +136.58% | 693B | ||
| +0.44% | +4.33% | +5.82% | -4.65% | 394B | ||
| -1.12% | -1.66% | +9.83% | +26.39% | 334B | ||
| -2.22% | -5.55% | -53.26% | -1.90% | 287B | ||
| +0.58% | +0.66% | -7.15% | -21.43% | 259B | ||
| -1.12% | -4.09% | -2.94% | +12.40% | 223B | ||
| -0.17% | -1.49% | -15.11% | -7.23% | 215B | ||
| -1.91% | -4.08% | -36.42% | -13.43% | 201B | ||
| -0.45% | -4.60% | -18.35% | -52.37% | 139B | ||
| Average | -0.58% | -2.03% | -13.86% | +9.35% | 290.4B | |
| Weighted average by Cap. | -0.23% | -1.81% | -11.71% | +30.92% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 35.31B 30.29B 28.22B 26.26B 48.45B 3,041B 54.1B 341B 129B 1,426B 132B 130B 5,240B | 35.98B 30.87B 28.76B 26.76B 49.38B 3,099B 55.13B 347B 131B 1,453B 135B 132B 5,340B |
| Net income | 6.68B 5.73B 5.34B 4.97B 9.17B 575B 10.24B 64.51B 24.35B 270B 25.06B 24.54B 992B | 7.52B 6.45B 6.01B 5.59B 10.32B 648B 11.52B 72.62B 27.41B 304B 28.2B 27.62B 1,116B |
| Net Debt | 45.14B 38.73B 36.08B 33.57B 61.94B 3,887B 69.16B 436B 165B 1,823B 169B 166B 6,699B | 39.39B 33.8B 31.49B 29.3B 54.06B 3,393B 60.36B 380B 144B 1,591B 148B 145B 5,847B |
More financial data
* Estimated data
Employees
28,000
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-07-18 | 294.76 $ | -1.17% | 1,967,676 |
| 25-07-17 | 298.25 $ | -0.26% | 1,725,609 |
| 25-07-16 | 299.02 $ | +2.23% | 1,881,075 |
| 25-07-15 | 292.51 $ | -1.52% | 1,593,010 |
| 25-07-14 | 297.03 $ | +0.60% | 1,202,396 |
Delayed Quote Nasdaq, July 18, 2025 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
294.76USD
Average target price
313.56USD
Spread / Average Target
+6.38%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition